scholarly journals Dynamics of Prostate-Specific Antigen Levels During Treatment with Testosterone Undecanoate in Patients with Type 2 Diabetes Mellitus

2012 ◽  
Vol 19 (4) ◽  
pp. 397-403 ◽  
Author(s):  
Rucsandra Dănciulescu Miulescu ◽  
Suzana Dănoiu ◽  
Denisa Margină ◽  
Sorin Păun ◽  
Cătălina Poiană
Keyword(s):  
Prostate Cancer ◽  
Type 2 Diabetes ◽  
Prostate Specific Antigen ◽  
Specific Antigen ◽  
Prostate Cancer Risk ◽  
Total Testosterone ◽  
Testosterone Replacement Therapy ◽  
Testosterone Undecanoate ◽  
History Of

AbstractObjectives. Prostate-specific antigen (PSA) is the most used and validated marker ofprostate cancer risk. The aim of this study was to assess PSA levels during treatmentwith testosteronum undecanoat in patients with type 2 diabetes (T2DM). Material and Methods. We evaluated 38 T2DM patients aged between 48 and 61 years withconfirmed hypogonadism. 1000 mg testosterone undecanoate was injectedintramuscular every 10 to 14 weeks. Total testosterone and PSA levels were assessedat baseline and after 6, 12, 24 months of treatment. Results. The average age was55.03 ± 2.40 years and 3 patients (7.89%) had a family history of prostate cancer.Treatment with testosterone undecanoate generated significant changes in serumtotal testosterone (482.29±50.78 ng/dl vs. 246.66±51.50 ng/dl, p < 0.001) but not inserum PSA levels (2.11±.0.49 ng/ml vs. 2.09±0.47 ng/ml, p - NS). Conclusion.Testosterone replacement therapy may normalize serum androgen levels but appearsto have little effect on PSA levels.

Correction of Androgen Deficiency in Men with Type 2 Diabetes

2021 ◽  
Vol 16 ◽  
Author(s):  
Volodymyr Pankiv ◽  
Tetyana Yuzvenko ◽  
Nazarii Kobyliak ◽  
Ivan Pankiv
Keyword(s):  
Type 2 Diabetes ◽  
Replacement Therapy ◽  
Testosterone Replacement ◽  
Control Group ◽  
Total Testosterone ◽  
Testosterone Replacement Therapy ◽  
Androgen Deficiency ◽  
Testosterone Undecanoate ◽  
Testosterone Levels

Background: In men with low levels of testosterone in the blood, it is believed that the symptoms can be regarded as an association between testosterone deficiency syndrome and related comorbidities. Aim: to investigate the effectiveness of testosterone therapy in patients with type 2 diabetes (T2D) and androgen deficiency. Materials and methods: Testosterone replacement therapy was carried out in 26 men with T2D and clinically or laboratory-confirmed androgen deficiency. The age of the subjects ranged from 35 to 69 years old. Laboratory studies included determinations of the concentration of the hormones estradiol, luteinizing hormone (LH), and prostate-specific antigen (PSA). The observation period was 9 months. Results: The average level of total blood testosterone in the subjects before treatment was 9.4 mol/l and was likely lower than that of the control group (19.3 ± 1.6 nmol/l). The levels of total testosterone in the subjects ranged from 3.9 nmol/l to 10.7 nmol/l, and hormone levels measuring less than 8.0 nmol/l were observed in only 11 patients. After a course of testosterone replacement therapy, a stabilization in total testosterone levels at the level of reference values (as compared to the start of treatment) was observed in the blood of men with T2D after 9 months of observation and the administration of the fourth injection (16.83 ± 0.75 nmol/l). Conclusion: The use of long-acting injectable testosterone undecanoate leads to normalization of total testosterone levels in the blood of men with T2D and androgen deficiency, and LH levels in these patients are unlikely to change.

Cumulative Prostate Cancer Risk Assessment with the Aid of the Free-to-Total Prostate Specific Antigen Ratio

2004 ◽  
Vol 45 (2) ◽  
pp. 160-165 ◽  
Author(s):  
Gunnar Aus ◽  
Charlotte Becker ◽  
Stefan Franzén ◽  
Hans Lilja ◽  
Pär Lodding ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Risk Assessment ◽  
Cancer Risk ◽  
Prostate Specific Antigen ◽  
Specific Antigen ◽  
Prostate Cancer Risk ◽  
Cancer Risk Assessment ◽  
Total Prostate Specific Antigen

Polymorphisms in the androgen receptor and the prostate-specific antigen genes and prostate cancer risk

The Prostate ◽  
2005 ◽  
Vol 65 (1) ◽  
pp. 58-65 ◽  
Author(s):  
Claudia A. Salinas ◽  
Melissa A. Austin ◽  
Elaine O. Ostrander ◽  
Janet L. Stanford
Keyword(s):  
Prostate Cancer ◽  
Androgen Receptor ◽  
Cancer Risk ◽  
Prostate Specific Antigen ◽  
Specific Antigen ◽  
Prostate Cancer Risk

Relationship of Prostate-Specific Antigen to Age and Testosterone in Men With Type 2 Diabetes Mellitus

2008 ◽  
Vol 14 (8) ◽  
pp. 1000-1005 ◽  
Author(s):  
Sandeep Dhindsa ◽  
Manish Upadhyay ◽  
Prabhakar Viswanathan ◽  
Susan Howard ◽  
Ajay Chaudhuri ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Prostate Specific Antigen ◽  
Specific Antigen ◽  
Relationship Of

Estimate of population coverage with the prostate specific antigen (PSA) test to screen for prostate cancer in a metropolitan area of northern Italy

2002 ◽  
Vol 9 (4) ◽  
pp. 179-180 ◽  
Author(s):  
A. Russo ◽  
M. Autelitano ◽  
A. Bellini ◽  
L. Bisanti
Keyword(s):  
Prostate Cancer ◽  
Prostate Specific Antigen ◽  
Specific Antigen ◽  
Health Information System ◽  
Northern Italy ◽  
Local Health ◽  
Male Population ◽  
High Coverage ◽  
Psa Test ◽  
History Of

The use of the prostate specific antigen (PSA) test in the period 1999–2000 in a population of 311 822 men, aged 40 years or more, resident in Milan, Italy, was examined. Data were drawn from the outpatient database of the local health information system. A total of 139 350 PSA tests were used in 83 943 subjects. Overall, 26.9% of the male population aged 40 or older, with no history of prostate cancer, received a PSA test in the 2 year study period. For subjects older than 50 the rate rose to 34%. Results show a high coverage of the male population in northern Italy with screening using the PSA test for prostate cancer.

scholarly journals Milk intake and the risk of type 2 diabetes mellitus, hypertension and prostate cancer

2009 ◽  
Vol 53 (5) ◽  
pp. 688-694 ◽  
Author(s):  
Ligia Araújo Martini ◽  
Richard James Wood
Keyword(s):  
Prostate Cancer ◽  
Type 2 Diabetes ◽  
Dairy Products ◽  
Prostate Cancer Risk ◽  
Renin Angiotensin System ◽  
Milk Intake ◽  
Current Evidence ◽  
High Calcium Intake ◽  
High Calcium

Milk intake is widely recommended for a healthy diet. Recent evidences suggest that milk/dairy products are associated with a lower risk of type 2 diabetes and hypertension. On the other hand, high calcium intake has been associated with a higher risk of prostate cancer. The calcium and vitamin D content in dairy foods could have beneficial effects on glucose metabolism and renin/angiotensin system as well regulates body weight. The association between high dairy/calcium consumption and prostate cancer risk are related to the presence of estrogens and insulin like growth factor (IGF-I) in milk. Based on the current evidence, it is possible that milk/dairy products, when consumed in adequate amounts and mainly with reduced fat content, has a beneficial effect on the prevention of hypertension and diabetes. Its potential role in the pathogenesis of prostate cancer is not well supported and requires additional study.

Sign in / Sign up

Export Citation Format

Share Document